JP2023059873A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023059873A5 JP2023059873A5 JP2023012793A JP2023012793A JP2023059873A5 JP 2023059873 A5 JP2023059873 A5 JP 2023059873A5 JP 2023012793 A JP2023012793 A JP 2023012793A JP 2023012793 A JP2023012793 A JP 2023012793A JP 2023059873 A5 JP2023059873 A5 JP 2023059873A5
- Authority
- JP
- Japan
- Prior art keywords
- genetically engineered
- seq
- amino acid
- chain variable
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002865 immune cell Anatomy 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 230000004807 localization Effects 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims 4
- 230000004068 intracellular signaling Effects 0.000 claims 4
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 3
- 230000014759 maintenance of location Effects 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 claims 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 claims 1
- -1 CD3ζ Proteins 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 claims 1
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 claims 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 claims 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 230000026647 proteasome localization Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025004349A JP2025065142A (ja) | 2016-11-22 | 2025-01-10 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662425398P | 2016-11-22 | 2016-11-22 | |
| US62/425,398 | 2016-11-22 | ||
| US201762543696P | 2017-08-10 | 2017-08-10 | |
| US62/543,696 | 2017-08-10 | ||
| JP2019547605A JP7778468B2 (ja) | 2016-11-22 | 2017-11-22 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
| PCT/US2017/063048 WO2018098306A1 (en) | 2016-11-22 | 2017-11-22 | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547605A Division JP7778468B2 (ja) | 2016-11-22 | 2017-11-22 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025004349A Division JP2025065142A (ja) | 2016-11-22 | 2025-01-10 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023059873A JP2023059873A (ja) | 2023-04-27 |
| JP2023059873A5 true JP2023059873A5 (https=) | 2023-06-14 |
Family
ID=62193475
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547605A Active JP7778468B2 (ja) | 2016-11-22 | 2017-11-22 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
| JP2023012793A Pending JP2023059873A (ja) | 2016-11-22 | 2023-01-31 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
| JP2025004349A Pending JP2025065142A (ja) | 2016-11-22 | 2025-01-10 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547605A Active JP7778468B2 (ja) | 2016-11-22 | 2017-11-22 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025004349A Pending JP2025065142A (ja) | 2016-11-22 | 2025-01-10 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10550183B2 (https=) |
| EP (1) | EP3545082A4 (https=) |
| JP (3) | JP7778468B2 (https=) |
| KR (2) | KR102889007B1 (https=) |
| CN (3) | CN110268049B (https=) |
| AU (3) | AU2017363278B2 (https=) |
| CA (1) | CA3043752A1 (https=) |
| NZ (1) | NZ752984A (https=) |
| SG (2) | SG10201912387PA (https=) |
| WO (1) | WO2018098306A1 (https=) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015116943A2 (en) | 2014-01-31 | 2015-08-06 | Monolith Materials, Inc. | Plasma torch design |
| KR102705340B1 (ko) | 2015-02-03 | 2024-09-09 | 모놀리스 머티어리얼스 인코포레이티드 | 카본 블랙 생성 시스템 |
| KR102763121B1 (ko) | 2015-02-06 | 2025-02-04 | 내셔널 유니버시티 오브 싱가포르 | 치료적 면역 세포의 효능의 향상 방법 |
| CA3032246C (en) | 2015-07-29 | 2023-12-12 | Monolith Materials, Inc. | Dc plasma torch electrical power design method and apparatus |
| CA2995081C (en) | 2015-08-07 | 2023-10-03 | Monolith Materials, Inc. | Method of making carbon black |
| EP3347306A4 (en) | 2015-09-09 | 2019-04-17 | Monolith Materials, Inc. | CIRCULAR SINGLE-LAYER GRAPH |
| KR102546839B1 (ko) | 2016-08-03 | 2023-06-23 | 워싱턴 유니버시티 | 키메라 항원 수용체를 이용한 t 세포 악성종양의 치료를 위한 car-t 세포의 유전자 편집 |
| NZ752984A (en) | 2016-11-22 | 2026-03-27 | Nat Univ Singapore | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies |
| CA3287539A1 (en) | 2017-06-21 | 2026-03-02 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF |
| US20190038733A1 (en) | 2017-08-10 | 2019-02-07 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
| EP3784776A4 (en) | 2018-05-23 | 2022-01-26 | National University of Singapore | Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies |
| US10227576B1 (en) | 2018-06-13 | 2019-03-12 | Caribou Biosciences, Inc. | Engineered cascade components and cascade complexes |
| US12227776B2 (en) | 2018-06-13 | 2025-02-18 | Caribou Biosciences, Inc. | Engineered cascade components and cascade complexes |
| EP3743512A4 (en) | 2018-10-31 | 2021-12-01 | Nantkwest, Inc. | ELIMINATION OF CD19 POSITIVE LYMPHOID MALIGNITIES BY CD19 CAR EXPRESSING NK CELLS |
| AU2019372673A1 (en) | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| MA53877A (fr) | 2018-11-14 | 2022-01-19 | MediSix Therapeutics Pte Ltd | Vecteurs à deux gènes pour la génération de cellules car-t et utilisations associées |
| CN109652379B (zh) * | 2018-12-29 | 2022-08-16 | 博生吉医药科技(苏州)有限公司 | Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用 |
| US11840575B2 (en) | 2019-05-07 | 2023-12-12 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Engineered immune cells targeting BCMA and their uses thereof |
| GB201914611D0 (en) * | 2019-10-09 | 2019-11-20 | Autolus Ltd | Engineered immune cell |
| CA3154218A1 (en) * | 2019-10-11 | 2021-04-15 | Crystal Mackall | Recombinant polypeptides for regulatable cellular localization |
| AU2020388690A1 (en) * | 2019-11-20 | 2022-06-09 | Cartherics Pty. Ltd. | Method for providing immune cells with enhanced function |
| JP2023504884A (ja) * | 2019-12-05 | 2023-02-07 | ヴィセリックス・インコーポレーティッド | ユニバーサル細胞療法のための免疫逃避機構のモジュレーター |
| US20230019849A1 (en) * | 2019-12-09 | 2023-01-19 | St. Jude Children's Research Hospital, Inc. | Method for Preparing CD7-Negative, CD3-Positive T Cells |
| US12312407B2 (en) * | 2020-01-30 | 2025-05-27 | St Phi Therapeutics Co., Ltd. | Universal T cells and the method of use thereof |
| CN112300282A (zh) * | 2020-11-03 | 2021-02-02 | 南京北恒生物科技有限公司 | 靶向cd7的人源化抗体及其用途 |
| CN114525259B (zh) * | 2020-11-03 | 2025-02-14 | 南京北恒生物科技有限公司 | 靶向cd7的嵌合抗原受体及其用途 |
| EP4243839A1 (en) | 2020-11-13 | 2023-09-20 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
| CN114525306B (zh) * | 2020-11-23 | 2025-01-28 | 博生吉医药科技(苏州)有限公司 | 一种cd7-car-t细胞的制备方法及应用 |
| AU2021386367A1 (en) | 2020-11-24 | 2023-06-22 | Les Laboratoires Servier | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| CN113234682B (zh) * | 2021-01-12 | 2023-02-21 | 上海雅科生物科技有限公司 | 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用 |
| WO2022161502A1 (zh) * | 2021-02-01 | 2022-08-04 | 羿尊生物医药（浙江）有限公司 | 一种靶向蛋白降解系统及其应用 |
| CN114853900A (zh) * | 2021-02-03 | 2022-08-05 | 南京北恒生物科技有限公司 | 新型嵌合抗原受体及其用途 |
| CN115044617B (zh) * | 2021-03-08 | 2024-08-13 | 河北森朗生物科技有限公司 | Car t细胞的制备方法、car t细胞及其应用 |
| CN112980800A (zh) * | 2021-03-08 | 2021-06-18 | 河北森朗生物科技有限公司 | Car-t细胞、其构建方法及其应用 |
| CN112662631B (zh) * | 2021-03-16 | 2021-06-29 | 合源生物科技(天津)有限公司 | 一种car-t细胞灌流培养方法 |
| CA3217028A1 (en) | 2021-04-22 | 2022-10-27 | Baylor College Of Medicine | Methods of engineering immune cells having reduced fratricidal activity |
| US20250222026A1 (en) * | 2021-06-08 | 2025-07-10 | Beijing Meikang Geno-Immune Biotechnology Co., Ltd. | Cd7-based humanized chimeric antigen receptor and use thereof |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250161358A1 (en) * | 2022-02-17 | 2025-05-22 | Utc Therapeutics (Shanghai) Co., Ltd. | Modified immune effector cells and uses thereof |
| CN114560943B (zh) * | 2022-02-28 | 2022-12-16 | 先进生物(苏州)有限公司 | Cd7-car-t细胞及其制备方法和应用 |
| US20250099504A1 (en) * | 2022-03-29 | 2025-03-27 | Institute Of Hematology And Blood Diseases Hospital , Chinese Academy Of Medical Sciences | Antibody that specifically binds to cd7 and use thereof in preparing chimeric antigen receptor |
| CN117004603A (zh) * | 2022-04-28 | 2023-11-07 | 南京北恒生物科技有限公司 | 一种cd7基因被敲除的工程化免疫细胞及其用途 |
| US20250387504A1 (en) | 2022-05-20 | 2025-12-25 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
| US20260061065A1 (en) | 2022-05-20 | 2026-03-05 | Novartis Ag | Antibody drug conjugates |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN116179495B (zh) * | 2022-11-28 | 2025-06-06 | 上海恩凯细胞技术有限公司 | 转基因免疫细胞及其应用 |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| EP4716750A1 (en) | 2023-05-23 | 2026-04-01 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| AR134424A1 (es) | 2023-11-22 | 2026-01-14 | Novartis Ag | Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos |
| EP4559937A1 (en) * | 2023-11-24 | 2025-05-28 | Universitat de Barcelona | Cd7 targeting moieties for the treatment of cd7 positive cancer |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| EP1015616A2 (en) | 1997-09-19 | 2000-07-05 | Dana Farber Cancer Institute, Inc. | Intrabody-mediated control of immune reactions |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| AU2002220265A1 (en) * | 2000-11-03 | 2002-05-15 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| WO2003051926A2 (en) | 2001-12-14 | 2003-06-26 | Friedrich-Alexander-Universitaet Erlangen-Nuernberg | Anti-cd7 immunotoxin as fusion protein |
| WO2005017163A2 (en) | 2003-08-15 | 2005-02-24 | Imperial College Innovations Limited | Phenotypic knockout of cell-surface proteins |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| AU2005259221B2 (en) | 2004-07-01 | 2011-02-10 | Innate Pharma | Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use |
| AU2005299353A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune, Llc | Use of modulators of EphA2 and EphrinA1 for the treatment and prevention of infections |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| WO2007044616A2 (en) | 2005-10-06 | 2007-04-19 | Xencor, Inc. | Optimized anti-cd30 antibodies |
| BRPI0808551B1 (pt) | 2007-03-01 | 2022-04-05 | Symphogen A/S | Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende |
| PT2185574E (pt) | 2007-09-07 | 2013-08-26 | Agensys Inc | Anticorpos e moléculas relacionadas que se ligam a proteínas 24p4c12 |
| KR20100110864A (ko) | 2008-01-24 | 2010-10-13 | 노보 노르디스크 에이/에스 | 인간화된 항-인간 ｎｋｇ2ａ 모노클로날 항체 |
| JP2013508287A (ja) | 2009-10-14 | 2013-03-07 | ヤンセン バイオテツク，インコーポレーテツド | 抗体を親和性成熟する方法 |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA3285826A1 (en) | 2012-02-22 | 2026-03-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| AU2013329186B2 (en) | 2012-10-10 | 2019-02-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| WO2014093831A2 (en) * | 2012-12-14 | 2014-06-19 | Thomson Reuters (Markets) Llc | Dynamic function builder |
| KR101521224B1 (ko) * | 2012-12-20 | 2015-05-19 | 한양대학교 산학협력단 | T 세포 특이적인 인간화 단일조각항체 전달체 |
| SG10201700916SA (en) | 2012-12-27 | 2017-03-30 | Aduro Biotech Inc | Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof |
| CN113005091A (zh) | 2013-02-06 | 2021-06-22 | 细胞基因公司 | 具有改进特异性的修饰的t淋巴细胞 |
| CN113684185A (zh) | 2013-02-26 | 2021-11-23 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| FI2997141T3 (fi) | 2013-05-13 | 2022-12-15 | CD19-spesifinen kimeerinen antigeenireseptori ja sen käyttöjä | |
| WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| KR102308597B1 (ko) | 2013-10-17 | 2021-10-01 | 내셔널 유니버시티 오브 싱가포르 | 다중 종양에 대항하여 항체-의존성 세포 세포독성을 촉발시키는 키메라 수용체 |
| MX373687B (es) | 2013-11-21 | 2020-07-07 | Ucl Business Ltd | Célula natural (nk) |
| WO2015121454A1 (en) | 2014-02-14 | 2015-08-20 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| PL3119807T3 (pl) | 2014-03-19 | 2019-09-30 | Cellectis | Specyficzne wobec cd123 chimeryczne receptory antygenowe do immunoterapii nowotworów |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| KR20170032406A (ko) | 2014-07-15 | 2017-03-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료를 위한 조작된 세포 |
| BR112017007003A2 (pt) | 2014-10-07 | 2017-12-19 | Cellectis | método para modulação de atividade de células imunes induzidas por car |
| PL3560953T3 (pl) | 2014-12-24 | 2024-05-13 | Autolus Limited | Komórka |
| KR102763121B1 (ko) | 2015-02-06 | 2025-02-04 | 내셔널 유니버시티 오브 싱가포르 | 치료적 면역 세포의 효능의 향상 방법 |
| JP7237449B2 (ja) * | 2015-02-27 | 2023-03-13 | アイセル・ジーン・セラピューティクス・エルエルシー | 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| WO2016138846A1 (en) | 2015-03-02 | 2016-09-09 | Shanghai Sidansai Biotechnology Co., Ltd | Reducing immune tolerance induced by pd‐l1 |
| GB201507104D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic acid construct |
| GB2592821B (en) | 2015-07-31 | 2022-01-12 | Univ Minnesota | Modified cells and methods of therapy |
| WO2017112877A1 (en) * | 2015-12-22 | 2017-06-29 | Icell Gene Therapeutics, Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| KR20180118175A (ko) | 2016-03-04 | 2018-10-30 | 노파르티스 아게 | 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도 |
| WO2017213979A1 (en) * | 2016-06-06 | 2017-12-14 | St. Jude Children's Research Hospital | Anti-cd7 chimeric antigen receptor and method of use thereof |
| CA2937157A1 (en) | 2016-07-25 | 2018-01-25 | Ucl Business Ltd | Protein-based t-cell receptor knockdown |
| KR102546839B1 (ko) | 2016-08-03 | 2023-06-23 | 워싱턴 유니버시티 | 키메라 항원 수용체를 이용한 t 세포 악성종양의 치료를 위한 car-t 세포의 유전자 편집 |
| NZ752984A (en) | 2016-11-22 | 2026-03-27 | Nat Univ Singapore | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies |
| US20190038733A1 (en) | 2017-08-10 | 2019-02-07 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
| MA53877A (fr) | 2018-11-14 | 2022-01-19 | MediSix Therapeutics Pte Ltd | Vecteurs à deux gènes pour la génération de cellules car-t et utilisations associées |
-
2017
- 2017-11-22 NZ NZ752984A patent/NZ752984A/en unknown
- 2017-11-22 CN CN201780073071.6A patent/CN110268049B/zh active Active
- 2017-11-22 SG SG10201912387PA patent/SG10201912387PA/en unknown
- 2017-11-22 CN CN202410674086.XA patent/CN118562882B/zh active Active
- 2017-11-22 SG SG11201903830TA patent/SG11201903830TA/en unknown
- 2017-11-22 US US15/821,170 patent/US10550183B2/en active Active
- 2017-11-22 CA CA3043752A patent/CA3043752A1/en active Pending
- 2017-11-22 WO PCT/US2017/063048 patent/WO2018098306A1/en not_active Ceased
- 2017-11-22 JP JP2019547605A patent/JP7778468B2/ja active Active
- 2017-11-22 EP EP17874643.4A patent/EP3545082A4/en active Pending
- 2017-11-22 AU AU2017363278A patent/AU2017363278B2/en active Active
- 2017-11-22 KR KR1020247020607A patent/KR102889007B1/ko active Active
- 2017-11-22 KR KR1020197016703A patent/KR20190085528A/ko not_active Ceased
- 2017-11-22 US US15/821,153 patent/US11440958B2/en active Active
- 2017-11-22 CN CN202410674061.XA patent/CN118581046A/zh active Pending
-
2022
- 2022-07-14 US US17/865,292 patent/US11945865B2/en active Active
- 2022-11-10 AU AU2022268355A patent/AU2022268355B2/en active Active
-
2023
- 2023-01-31 JP JP2023012793A patent/JP2023059873A/ja active Pending
-
2024
- 2024-02-21 US US18/583,551 patent/US20240182567A1/en active Pending
-
2025
- 2025-01-10 JP JP2025004349A patent/JP2025065142A/ja active Pending
- 2025-07-04 AU AU2025205147A patent/AU2025205147B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023059873A5 (https=) | ||
| JP2025065142A5 (https=) | ||
| JP2021137024A5 (https=) | ||
| JP2021106605A5 (https=) | ||
| JP2021177771A5 (https=) | ||
| JP7746323B2 (ja) | Ｐｄ－１及び４－１ｂｂの融合タンパク質 | |
| US10808019B2 (en) | Nucleic acid molecules encoding cytokine fusion proteins comprising tumor necrosis factor (TNF) superfamily ligands | |
| JP2022534680A5 (https=) | ||
| JP2023527049A5 (https=) | ||
| JP2021094037A5 (https=) | ||
| JP2023071729A5 (https=) | ||
| JP2022109953A5 (https=) | ||
| JP2020512005A5 (https=) | ||
| JP2020114264A5 (https=) | ||
| JP2024502632A5 (https=) | ||
| JP2019527557A5 (https=) | ||
| JP2018525006A5 (https=) | ||
| JP2021512615A5 (https=) | ||
| JP2022536581A5 (https=) | ||
| JP2020511136A5 (https=) | ||
| AU2018277301B2 (en) | Heterodimerizing Ig domains | |
| JP2018525033A5 (https=) | ||
| JP2020513829A5 (https=) | ||
| JP2024023228A5 (https=) | ||
| FI4063397T3 (fi) | Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi |